Exelixis Inc Proceeds from Divestiture of Businesses
Exelixis Inc (EXEL) reported Proceeds from Divestiture of Businesses of $838.00 thousand for the 12-month period ending 2014-12-31, per its 10-K filed 2015-03-02.
Discontinued › Cash Flow › Investing Activities
us-gaap:ProceedsFromDivestitureOfBusinesses · last filed 2015-03-02
- Exelixis Inc proceeds from divestiture of businesses for the quarter ending 2014-12-31 was $0.00.
- Exelixis Inc proceeds from divestiture of businesses for the quarter ending 2013-12-31 was $0.00.
- Exelixis Inc proceeds from divestiture of businesses for the quarter ending 2012-12-31 was $0.00.
- Exelixis Inc proceeds from divestiture of businesses for the quarter ending 2011-12-31 was $0.00, a 100.00% decline year-over-year.
- Exelixis Inc proceeds from divestiture of businesses for fiscal 2014 was $838.00K.
- Exelixis Inc proceeds from divestiture of businesses for fiscal 2013 was $0.00.
- Exelixis Inc proceeds from divestiture of businesses for fiscal 2012 was $0.00, a 100.00% decline from fiscal 2011.
- Exelixis Inc proceeds from divestiture of businesses for fiscal 2011 was $3.01M, a 66.56% decline from fiscal 2010.
| Period end | Proceeds from Divestiture of Businesses 3 month | Proceeds from Divestiture of Businesses 6 month | Proceeds from Divestiture of Businesses 9 month | Proceeds from Divestiture of Businesses 12 month |
|---|---|---|---|---|
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-02 | $838.00K 10-K · filed 2015-03-02 | ||
| 2014-09-30 | $838.00K 10-Q · filed 2014-11-04 | |||
| 2013-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-02 | $0.00 10-K · filed 2015-03-02 | ||
| 2013-09-30 | $0.00 10-Q · filed 2014-11-04 | |||
| 2012-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-02 | $0.00 10-K · filed 2015-03-02 | ||
| 2012-09-30 | $0.00 10-Q · filed 2012-11-07 | |||
| 2011-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-20 | $3.01M 10-K · filed 2014-02-20 | ||
| 2011-09-30 | $3.01M 10-Q · filed 2012-11-07 | |||
| 2010-12-31 | $400.00K derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-21 | $400.00K derived: sum of 2 quarters · filed 2013-02-21 | $9.00M 10-K · filed 2013-02-21 | |
| 2010-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2011-10-27 | $8.60M 10-Q · filed 2011-10-27 | ||
| 2010-06-30 | $8.60M 10-Q · filed 2011-08-04 | |||
| 2009-12-31 | $2.20M 10-K · filed 2012-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |